Your Alzheimer’s Questions Answered: Q&A with Rudy Tanzi

We collected your questions about Alzheimer’s from our fall symposium and social media and presented them to Dr. Rudy Tanzi, chairman of our Research Consortium. Watch the videos below! Q&A with Dr. Rudy Tanzi: Alzheimer’s & Genetics Video of Q&A with Dr. Rudy Tanzi: Alzheimer's & Genetics Part 1: Alzheimer’s and ...

April 17, 2014

A NEW AND IMPROVED PROTOCOL FOR STUDYING TAUOPATHIES

Alzheimer’s disease (AD) is characterized by the presence of amyloid-beta (Aβ) plaques and tau neurofibrillary tangles (NFTs). Despite this knowledge, scientists do not know how these tau tangles develop in the first place. A new study published in Cell Reports by Anthony Fitzpatrick, Ph.D. of Columbia University, and Leonard Petrucelli, Ph.D. of ...

March 16, 2021

Genes to Therapies: One Year Later

In just its first year of operation, Cure Alzheimer’s Fund’s ambitious new Genes to Therapies™ (G2T) research program has bloomed far beyond expectations. “We’re firing on all cylinders now,” says Research Consortium Chair Dr. Rudy Tanzi. “It’s exactly where we need to be headed to stop this disease.” In 2015, Cure Alzheimer’s ...

February 12, 2016

Robert Kiss

One America Charity Ride 3,200 Mile Update – April 25, 2017 When I last reported, I was just recovering from bruised ribs in Louisville.  I am happy to report that I am now feeling much better in Confluence, PA.  On the home stretch now. Some of you have asked if there would be a ...

April 27, 2018

The Search for New Ways to Treat Alzheimer’s Disease

By John R. Cirrito, Ph.D., and David M. Holtzman, M.D.Microdialysis Core Facility, Department of Neurology, Hope Center for Neurological Diseases, Washington University, St. Louis, MO A major contributing factor in Alzheimer’s disease is the elevation of a protein called amyloid-β, or Aβ. Since high levels of Aβ play a role in ...

August 20, 2009

Groundbreaking Alzheimer’s Disease Blood Test Subject of Upcoming Webinar

Cure Alzheimer’s Fund will host Dr. David Holtzman for a live webinar on Thursday, May 27 at 5:30 PM.  Diagnosing Alzheimer’s Disease: A Groundbreaking New Blood Test is free and open to the public. Registration is required. Dr. Holtzman is a co-inventor of a new blood test, PrecivityAD, designed to assist ...

May 20, 2021

How Can We Overcome Alzheimer’s?

Below is the text from an article included on the Eureka blog which provides an overview of the need for a multi-pronged approach to stopping Alzheimer’s disease. The work of Dr.’s Rudy Tanzi and David Holtzman, and the late Stephen Wagner, of the Cure Alzheimer’s Fund Research Leadership Group, is ...

November 2, 2023

A Major Achievement! The Alzheimer’s Genome Project

The Alzheimer’s Genome Project™ (AGP) , funded by Cure Alzheimer’s Fund (CAF), is making great scientific progress. This work is providing new understanding of AD pathology and revealing novel genetic information. The more we know about how the disease works, the better the chances are for identifying therapeutic intervention and ...

December 15, 2010

Alzheimer’s Genes in the News: What does it all mean?

Setting the stage The 10th Annual International Conference on Alzheimer’s Disease/Parkinson’s Disease (AD/PD) was held this March in Barcelona with thousands of researchers from 68 countries attending. Chief among the topics of interest was determining risk for the disease from genetics. The useful source for all things Alzheimer’s, The Alzheimer’s Research ...

April 7, 2011

Neuroimmune Consortium: Examining the Role of Human Microglia in the Transition Between Parenchymal and Vascular Amyloid Beta Pathology

2022 Genetic and neuropathological studies have strongly implicated microglia in the development and progression of Alzheimer’s disease (AD). Yet precisely how AD risk genes alter microglial function to impact amyloid beta pathology remains unclear. One popular hypothesis is that microglial risk genes reduce amyloid beta clearance from the brain by impairing ...

December 18, 2020

Mathew Blurton-Jones